Overview

This trial is active, not recruiting.

Condition age-related macular degeneration
Treatment drawing blood
Sponsor Rudolf Foundation Clinic
Start date July 2006
End date November 2007
Trial identifier NCT00533754, EK 06-076-VK

Summary

The aim of the study is to show a higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals.

Additionaly a correlation between a subsided infection with chlamydia and patients with AMD and a factor H polymorphism will be investigated. An interrelationship with the VEGF-plasma level shall give more hints into the pathomechanism of AMD.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking single blind (outcomes assessor)
Primary purpose basic science

Primary Outcomes

Measure
higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals
time frame:

Secondary Outcomes

Measure
a correlation between a subsided infection with chlamydia and patients with AMD and a factor H polymorphism will be investigated. An interrelationship with the VEGF-plasma level shall give more hints into the pathomechanism of AMD
time frame:

Eligibility Criteria

Male or female participants at least 55 years old.

Inclusion Criteria: - man and women over 18 years old - Filled out informed consentBereitschaft zur Teilnahme - Diagnosis of non-exudative/ exudative age related macular dgeneneration Exclusion Criteria: - inherited retinal diseases - other aquired retinal/ macular - missing informed consent

Additional Information

Official title Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population
Trial information was received from ClinicalTrials.gov and was last updated in September 2007.
Information provided to ClinicalTrials.gov by Rudolf Foundation Clinic.